Real-world Study of Dedifferentiated Liposarcoma Patients in China

Demographic, Clinical Characteristics, and Treatment Outcomes Associated With Dedifferentiated Liposarcoma Patients in China

NCT06115681•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
•Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
•At least 18 years old at the date of initial diagnosis.

Locations (1)

Beijing Jishuitan hospital

Beijing, China

Key Dates

Start Date

March 13, 2024

Primary Completion Date

May 15, 2024

Completion Date

May 15, 2024

Last Updated

July 10, 2025

Enrollment

1,390

ACTUAL participants

Conditions

Dedifferentiated Liposarcoma

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

NCT06389799

Dedifferentiated Liposarcoma

View study

ACTIVE_NOT_RECRUITINGPHASE2

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

NCT05694871

Advanced Dedifferentiated LiposarcomaLocally Advanced Dedifferentiated Liposarcoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Real-world Study of Dedifferentiated Liposarcoma Patients in China

Inclusion Criteria

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors